Recent Updates
Recently added Catalysts
ALGS Positive Sentiment

Preclinical characterization of ALG-093940, a potent and orally bioavailable small molecule PD-1/PD-L1 inhibitor for the treatment of chronic hepatitis B infection and liver cancer

Thursday, May 28, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the preclinical characterization of ALG-093940, a small molecule inhibitor targeting PD-1/PD-L1 pathways. This compound is being developed for the treatment of chronic hepatitis B infection and liver cancer. Its oral bioavailability may improve patient adherence to treatment regimens.
Price reaction · baseline $5.6 (2026-05-27 close) · hit pre-market · 1 other ALGS headline(s) in the window, move may be shared
day 0 close · peak
+3.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • ALG-093940 shows promise as a potent PD-1/PD-L1 inhibitor.
  • The molecule is orally bioavailable, enhancing patient compliance.
  • It targets chronic hepatitis B and liver cancer, addressing significant health issues.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+153%
120-day peak, hindsight
Typical move
6.1%
average across 6 past catalysts
Cash runway
~3 mo
High dilution risk
Lead asset
ALG-055009
Phase 2 · NASH

Full Press Release Details

• About Overview Management Board of Directors
• Science Pipeline Posters & Presentations
• Patients Chronic HBV Infection MASH Clinical Trials Expanded Access Policy
• News & Media Press Releases Presentations & Events
• Investors Overview Stock Stock Quote & Chart Analyst Coverage News & Events News Releases Investor Calendar Financials SEC Filings Quarterly Results Governance Governance Highlights Committee Composition Resources Investor FAQs Email Alerts Contact IR
• Careers
• Overview
• Management
• Board of Directors
• Pipeline
• Posters & Presentations
• Chronic HBV Infection
• MASH
• Clinical Trials
• Expanded Access Policy
• Press Releases
• Presentations & Events
• Overview
• Stock Stock Quote & Chart Analyst Coverage
• News & Events News Releases Investor Calendar
• Financials SEC Filings Quarterly Results
• Governance Governance Highlights Committee Composition
• Resources Investor FAQs Email Alerts Contact IR
• Stock Quote & Chart
• Analyst Coverage
• News Releases
• Investor Calendar
• SEC Filings
• Quarterly Results
• Governance Highlights
• Committee Composition
• Investor FAQs
• Email Alerts
• Contact IR

Frequently Asked Questions

What is ALG-093940?

ALG-093940 is a small molecule PD-1/PD-L1 inhibitor aimed at treating chronic hepatitis B and liver cancer.

How does ALG-093940 work?

It inhibits the PD-1/PD-L1 pathway, which is crucial in regulating immune responses against tumors.

What are the benefits of ALG-093940?

Its oral bioavailability may enhance patient compliance compared to injectable therapies.

What conditions does ALG-093940 target?

It is being developed for chronic hepatitis B infection and liver cancer.

ShareAdd on Google
Tags: ALGS Viatris Investor Conferences Healthcare ALG-093940 PD-1 inhibitor chronic hepatitis B liver cancer oral bioavailability
Last updated: May 28, 2026

Biotech snapshot

Cash runway
$30M liquidity · $8M/mo burn
~3 mo
High dilution risk
Lead asset
ALG-055009Phase 2
NASH →

Catalyst track record

+153%
best trade around ALGS's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for ALGS.

See every catalyst's timing & PoA →